8-K: Amicus Therapeutics Completes Merger with BioMarin
Current Report (Form 8-K) - Merger Completion
Amicus Therapeutics, Inc. has been acquired by BioMarin Pharmaceutical Inc. through a merger, with shareholders receiving $14.50 per share in cash.
Summary
- Amicus Therapeutics, Inc. has been acquired by BioMarin Pharmaceutical Inc. via a merger, effective April 27, 2026.
- Each outstanding share of Amicus common stock was converted into $14.50 in cash.
- Outstanding stock options and RSUs were also cancelled and converted into cash payments.
- All outstanding indebtedness under the Amicus Credit Agreement has been repaid and terminated.
- Amicus Therapeutics' common stock will be delisted from the Nasdaq Global Select Market.
- The company's reporting obligations under the Exchange Act will be terminated following delisting.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive outcome for Amicus shareholders, providing a significant cash return, though it marks the end of the company's independent journey.
Positives
- Shareholders received a cash payment of $14.50 per share, providing immediate value.
- All outstanding debt has been fully repaid, simplifying the capital structure.
- The merger provides a clear exit for Amicus shareholders.
Negatives
- Amicus Therapeutics will cease to be an independent publicly traded entity.
- Shareholders will no longer participate in the future growth or potential of Amicus as a standalone company.
Risks
- Potential for integration challenges between Amicus and BioMarin.
- Uncertainty regarding the future strategic direction and operational focus of the combined entity.
Future Outlook
As Amicus Therapeutics is now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., its future outlook is integrated into BioMarin's strategic plans. Specific forward-looking statements for Amicus as a standalone entity are no longer applicable.
Management Comments
- The resignations of Amicus directors were not a result of any disagreement regarding the company's operations, policies, or practices.
- The directors of Merger Sub (Eric Davis and Brian Mueller) became the directors of the Surviving Corporation (Amicus Therapeutics).
Industry Context
StockSavvy.ai notes that this merger represents continued consolidation within the biotechnology sector, driven by the pursuit of complementary pipelines and market expansion. BioMarin's acquisition of Amicus Therapeutics likely aims to strengthen its rare disease portfolio.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Michael G. Raab, Bradley L. Campbell, Lynn D. Bleil, Michael A. Kelly, Margaret G. McGlynn, Eiry W. Roberts, M.D., Glenn P. Sblendorio, Craig A. Wheeler, Burke W. Whitman | Eric Davis, Brian Mueller | April 27, 2026 | Resignation of existing directors and appointment of Merger Sub directors following the completion of the merger. |
| Executive Officer | Bradley L. Campbell, Simon Harford, Ellen S. Rosenberg, David M. Clark, Jeffrey P. Castelli | Eric Davis (President and Secretary), Brian Mueller (Treasurer) | April 27, 2026 | Cessation of existing executive officers and appointment of Merger Sub officers to the Surviving Corporation. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amended and Restated Certificate of Incorporation | The company's certificate of incorporation was amended and restated in its entirety to conform to the terms of the Merger Agreement. | April 27, 2026 | Reflects the change in corporate structure and ownership following the merger. |
| Amended and Restated Bylaws | The company's bylaws were amended and restated to conform to the bylaws of Merger Sub prior to the merger. | April 27, 2026 | Aligns corporate governance procedures with those of the acquiring entity. |
Stakeholder Impact
- Shareholders: Receive $14.50 per share in cash, realizing their investment.
- Employees: Potential for changes in roles, responsibilities, and employment terms under new ownership.
- Creditors: Indebtedness under the Amicus Credit Agreement has been fully repaid.
- Board of Directors: All existing directors resigned; new directors appointed from Merger Sub.
Next Steps
- Delisting of Amicus Therapeutics common stock from Nasdaq.
- Termination of Amicus Therapeutics' reporting obligations under the Exchange Act.
- Integration of Amicus Therapeutics' operations and assets into BioMarin Pharmaceutical Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-10-02 | Date of the Amicus Credit Agreement. |
| 2025-12-19 | Date of the Agreement and Plan of Merger. |
| 2026-04-27 | Effective date of the Merger and completion of the acquisition. |
| 2026-04-27 | Date Amicus notified Nasdaq of merger consummation and intent to delist. |
| 2026-04-28 | Date Amicus Common Stock will be suspended from trading on Nasdaq. |
Recommendation
holdThe acquisition provides a definitive cash exit for existing shareholders at a premium. For potential new investors, the company is no longer independently traded, making a traditional buy/sell/hold recommendation on Amicus Therapeutics stock moot. The value is now tied to BioMarin Pharmaceutical Inc.
Keywords
merger, acquisition, BioMarin Pharmaceutical, Amicus Therapeutics, cash consideration, delisting, Nasdaq, Form 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.